CST13P: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Target Name: CST13P

NCBI ID: G164380

CST13P

Other Name(s): cystatin 13, pseudogene | CTES6 | CSTT | Cystatin 13, pseudogene

CST13P: A Potential Drug Target and Biomarker for Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide, leading to significant morbidity and mortality. Chronic obstructive pulmonary disease is characterized by chronic coughing, wheezing, coughing up phlegm, and shortness of breath, which are caused by the continuous obstruction of the airways. According to the World Health Organization (WHO), COPD is estimated to have 177 million subscribers worldwide, and its incidence is expected to reach 222 million by the year 2030.

COPD is a chronic progressive disease that can be caused by various factors, including genetics, environmental factors, and lifestyle. Currently, there are several medications that are used to treat COPD, including bronchodilators, corticosteroids, and lung volume expanders. However, these medications have several limitations, including their side effects and the fact that they do not always provide long-term improvement in symptoms.

CST13P is a protein that is expressed in the airways of people with COPD. It is a cytoplasmic protein that is involved in cell signaling and is known to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis. Studies have shown that CST13P is overexpressed in people with COPD, and that it is associated with poor prognosis and quality of life.

In addition, CST13P has been shown to be involved in the regulation of surfactant production in the airways of people with COPD. Surfactants are a type of protein that helps to reduce surface tension in the airways, making it easier for air to flow in and out. In people with COPD, the production of surfactants is defective, leading to surface tension that can cause airway obstruction. CST13P has been shown to be involved in the regulation of surfactant production in the airways of people with COPD, and may be a potential drug target for COPD.

CST13P has also been shown to be involved in the regulation of cellular signaling in the airways of people with COPD. It has been shown to be involved in the regulation of T cell development and function, and has been shown to play a role in the regulation of inflammation in the airways. These functions may be important in the development and progression of COPD.

In conclusion, CST13P is a protein that is expressed in the airways of people with COPD, and has been shown to be involved in the regulation of cell signaling and surfactant production in the airways. These functions make CST13P a potential drug target for COPD. Further research is needed to determine the exact role of CST13P in the development and progression of COPD, and to identify potential small molecules that can inhibit its activity.

Protein Name: Cystatin 13, Pseudogene

The "CST13P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CST13P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets